Nasopharyngeal carcinoma is known to highly involve neck node and distant site. Since early in 1970, chemotherapy has been studied for the treatment of this disease. Numbers of positive results have been reported. Despite such promising results, no randomized trial testing added value of chemotherapy has yet been reported, and it remains to be shown in a randomized trial whether the additions of chemotherapy to conventional treatment could improve patient's outcome. In this paper, the author analyzed the results of chemotherapy for nasopharyngeal carcinoma from the literature. For the neoadjuvant chemotherapy, International Nasopharynx Cancer Study Group reported that there is a significant increase in 3 year disease free survival. Thus neoadjuvant chemotherapy should be indicated for stage III, IV with advanced neck node disease, up to 3 cycles by combination chemotherapy that has some certain magnitude of activity. Simultaneous chemo-radiotherapy has a role in advanced T-stage cases, since main purpose of this treatment modality is local control. Al-Sarrf reported the therapeutic benefit in adjuvant chemotherapy. Adjuvant chemotherapy should be applied for stage III, IV patients with poor prognosis who consider to cause distant metastasis. An outpatient setting chemotherapy regimen that has some certain magnitude of activity is thought to ideal for adjuvant chemotherapy.
View full abstract